Inhibiting IL-13 Receptor-Expressing Cancer Cells with Anti-IL-13 Receptor Immunotoxin and Alkylating Agents
Description of Invention:
The present invention relates to methods of inhibiting the growth of cancer cells expressing the IL-13 receptor. Most generally, the patent application claims immunotoxins consisting of anti-IL-13 antibodies bound to toxins such as pseudomonas exotoxin or diphtheria toxin, or a cytotoxic fragment thereof, used in combination with alkylating agents. This combination appears to have significant advantages over use of either agent alone in the treatment of malignant gliomas, head and neck cancers, adenocarcinomas of the colon, stomach of skin, and Hodgkin’s disease.
Inventors:
Raj Puri and Syed Husain (FDA)
Patent Status:
DHHS Reference No. E-302-2003/0-US-01 -- U.S. Provisional Application No. 60/621,035 filed 20 Oct 2004
Portfolios: Cancer
Cancer -Diagnostics-In Vitro-MAb Based Cancer -Diagnostics-In Vivo-MAb Cancer -Therapeutics-Immunoconjugates-Mab Cancer -Diagnostics Cancer -Therapeutics
For Additional Information Please Contact: David A. Lambertson Ph.D.
NIH Office of Technology Transfer
6011 Executive Blvd, Suite 325
Rockville, MD 20852-3804
Phone: (301)435-4632
Email: lambertsond@mail.nih.gov
Fax: (301) 402-0220
